Minireview: Role of intracellular scaffolding proteins in the regulation of endocrine g protein-coupled receptor signaling

Molecular Endocrinology

Volumn 29, Issue 6, 2015, Pages 814-830

  Walther, Cornelia ^a   Ferguson, Stephen S G ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; G PROTEIN COUPLED RECEPTOR; JANUS KINASE 2; PDZ PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN 14 3 3; RETINA S ANTIGEN; SCAFFOLD PROTEIN;

ANXIETY; ARTICLE; DIABETES MELLITUS; ENDOCRINE SYSTEM; ENDOCRINE TUMOR; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; OBESITY; OSTEOPOROSIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; REGULATORY MECHANISM; STRESS; ANIMAL; BIOLOGICAL MODEL; DISEASES; INTRACELLULAR SPACE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE; ENDOCRINE SYSTEM; HUMANS; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84930857717     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1091     Document Type: Article

References (218)

1. Jassal B, Jupe S, Caudy M, et al. The systematic annotation of the three main GPCR families in Reactome. Database (Oxford). 2010; 2010:baq018.
2. Luttrell LM. Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors. Mol Biotechnol. 2008;39:239–264.
3. Schoneberg T, Schulz A, Biebermann H, Hermsdorf T, Rompler H, Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther. 2004;104:173–206.
4. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256-1272.
5. Kamal M, Jockers R. Biological significance of GPCR heteromer-ization in the neuro-endocrine system. Front Endocrinol (Lausanne). 2011;2:2.
6. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002;520:97-101.
7. Thompson MD, Cole DE, Jose PA. Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. Methods Mol Biol. 2008;448:77-107.
8. Lundstrom K. An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs. Methods Mol Biol. 2009;552:51-66.
9. Vassart G, Costagliola S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol. 2011;7:362-372.
10. Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell. 1995;80:249-257.
11. Ferguson SS. Evolving concepts in G protein-coupled receptor en-docytosis: the role in receptor desensitization and signaling. Pharmacol Rev. 2001;53:1-24.
12. Hall RA, Premont RT, Lefkowitz RJ. Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol. 1999;145: 927-932.
13. Luttrell LM, Ferguson SS, Daaka Y, et al. /3-Arrestin-dependent formation of /32 adrenergic receptor-Src protein kinase complexes. Science. 1999;283:655-661.
14. Rajagopal K, Lefkowitz RJ, Rockman HA. When 7 transmembrane receptors are not G protein-coupled receptors. J Clin Invest. 2005;115:2971-2974.
15. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharmacol Ther. 2004;103:203-221.
16. Bockaert J, Perroy J, Becamel C, Marin P, Fagni L. GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies. Annu Rev Pharmacol Toxicol. 2010;50:89-109.
17. Magalhaes AC, Dunn H, Ferguson SS. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. BrJ Pharmacol. 2012;165:1717-1736.
18. Maurice P, Guillaume JL, Benleulmi-Chaachoua A, Daulat AM, Kamal M, Jockers R. GPCR-interacting proteins, major players of GPCR function. Adv Pharmacol. 2011;62:349-380.
19. Dunn HA, Ferguson SS. PDZ protein regulation of GPCR trafficking and signaling pathways [published online March 25, 2015]. Mol Pharmacol. doi:10.1124/mol.115.098509.
20. Hall RA, Lefkowitz RJ. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res. 2002;91:672-680.
21. Ferguson SS, Downey WE, Colapietro AM, Barak LS, Menard L, Caron MG. Role of /3-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996;271:363-366.
22. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res. 1996;51:319-351; discussion 352-353.
23. Goodman OB Jr, Krupnick JG, Santini F, et al. /3-Arrestin acts as a clathrin adaptor in endocytosis of the /32-adrenergic receptor. Nature. 1996;383:447-450.
24. Jean-Alphonse F, Hanyaloglu AC. Regulation of GPCR signal networks via membrane trafficking. Mol Cell Endocrinol. 2011; 331:205-214.
25. Laporte SA, Oakley RH, Zhang J, et al. The /32-adrenergic recep-tor//3arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA. 1999;96:3712-3717.
26. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and /3-arrestins in receptor signaling and desensitization. J Biol Chem. 1998;273:18677-18680.
27. Walther C, Ferguson SS. Arrestins: role in the desensitization, sequestration, and vesicular trafficking of G protein-coupled receptors. Prog Mol Biol Transl Sci. 2013;118:93-113.
28. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356-363.
29. Lambright DG, Sondek J, Bohm A, Skiba NP, Hamm HE, Sigler PB. The 2.0 A crystal structure of a heterotrimeric G protein. Nature. 1996;379:311-319.
30. Hamm HE, Gilchrist A. Heterotrimeric G proteins. Curr Opin Cell Biol. 1996;8:189-196.
31. Milligan G, Kostenis E. Heterotrimeric G-proteins: a short history. Br J Pharmacol. 2006;147(suppl 1):S46-S55.
32. Offermanns S. G-proteins as transducers in transmembrane signalling. Prog Biophys Mol Biol. 2003;83:101-130.
33. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem. 1998;273:17979-17982.
34. Galandrin S, Bouvier M. Distinct signaling profiles of /31 and /32 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006;70:1575-1584.
35. Jin LQ, Wang HY, Friedman E. Stimulated D(1) dopamine receptors couple to multiple G« proteins in different brain regions. J Neurochem. 2001;78:981-990.
36. Laugwitz KL, Allgeier A, Offermanns S, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci USA. 1996;93:116-120.
37. Luttrell LM. Minireview: more than just a hammer: ligand “bias” and pharmaceutical discovery. Mol Endocrinol. 2014;28:281-294.
38. Offermanns S, Wieland T, Homann D, et al. Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. Mol Pharmacol. 1994;45:890-898.
39. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev. 2010;62:305-330.
40. Irannejad R, Tomshine JC, Tomshine JR, et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature. 2013;495:534-538.
41. Irannejad R, von Zastrow M. GPCR signaling along the endocytic pathway. Curr Opin Cell Biol. 2014;27:109-116.
42. Tsvetanova NG, Irannejad R, von Zastrow M. G Protein-coupled receptor (GPCR) signaling via heterotrimeric G proteins from endosomes. J Biol Chem. 2015;290:6689-6696.
43. Vilardaga JP, Jean-Alphonse FG, Gardella TJ. Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol. 2014;10:700-706.
44. Calebiro D, Nikolaev VO, Gagliani MC, et al. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol. 2009;7:e1000172.
45. Ferrandon S, Feinstein TN, Castro M, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol. 2009;5:734-742.
46. Wehbi VL, Stevenson HP, Feinstein TN, Calero G, Romero G, Vilardaga JP. Noncanonical GPCR signaling arising from a PTH receptor-arrestin-G/37 complex. Proc Natl Acad Sci USA. 2013; 110:1530-1535.
47. Feinstein TN, Yui N, Webber MJ, et al. Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem. 2013;288:27849-27860.
48. Barauna VG, Magalhaes FC, Campos LC, et al. Shear stress-induced Ang II AT1 receptor activation: G-protein dependent and independent mechanisms. Biochem Biophys Res Commun. 2013; 434:647-652.
49. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling acti- vates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem. 2002;277:9268-9277.
50. Zhai P, Yamamoto M, Galeotti J, et al. Cardiac-specific overex-pression of AT1 receptor mutant lacking Gaq/Gai coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest. 2005;115:3045-3056.
51. Rajagopal S, Kim J, Ahn S, et al. /3-Arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci USA. 2010;107:628-632.
52. Christopoulos A. Advances in G protein-coupled receptor allos-tery: from function to structure. Mol Pharmacol. 2014;86:463-478.
53. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55: 597-606.
54. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov. 2002;1: 198-210.
55. Christopoulos A, Kenakin T. G protein-coupled receptor alloster-ism and complexing. Pharmacol Rev. 2002;54:323-374.
56. Wootten D, Christopoulos A, Sexton PM. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov. 2013;12:630-644.
57. Kenakin T, Miller LJ. Seven transmembrane receptors as shape-shifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010; 62:265-304.
58. Luttrell LM, Kenakin TP. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol. 2011; 756:3-35.
59. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013;12:205-216.
60. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of /3-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012;52:179-197.
61. Shonberg J, Lopez L, Scammells PJ, Christopoulos A, Capuano B, Lane JR. Biased agonism at G protein-coupled receptors: the promise and the challenges—a medicinal chemistry perspective. Med Res Rev. 2014;34:1286-1330.
62. Stallaert W, Christopoulos A, Bouvier M. Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov. 2011;6:811-825.
63. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320:1-13.
64. Shukla AK. Biasing GPCR signaling from inside. Sci Signal. 2014; 7:pe3.
65. Garbett D, Bretscher A. The surprising dynamics of scaffolding proteins. Mol Biol Cell. 2014;25:2315-2319.
66. Sheng M, Sala C. PDZ domains and the organization of supramo-lecular complexes. Annu Rev Neurosci. 2001;24:1-29.
67. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of /3-ar-restin-dependent seven transmembrane receptor signaling. Trends Biochem Sci. 2011;36:457-469.
68. Gurevich VV, Gurevich EV. Extensive shape shifting underlies functional versatility of arrestins. Curr Opin Cell Biol. 2014;27: 1-9.
69. Puca L, Brou C. a-Arrestins—new players in Notch and GPCR signaling pathways in mammals.JCellSci. 2014;127:1359-1367.
70. Nabhan JF, Pan H, Lu Q. Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to mediate ubiquitination of the /32-adrenergic receptor. EMBO Rep. 2010;11:605-611.
71. Shea FF, Rowell JL, Li Y, Chang TH, Alvarez CE. Mammalian a arrestins link activated seven transmembrane receptors to Nedd4 family e3 ubiquitin ligases and interact with /3 arrestins. PLoS One. 2012;7:e50557.
72. Han SO, Kommaddi RP, Shenoy SK. Distinct roles for /3-arrestin2 and arrestin-domain-containing proteins in /32 adrenergic receptor trafficking. EMBO Rep. 2013;14:164-171.
73. Gurevich VV, Benovic JL. Visual arrestin interaction with rhodop-sin. Sequential multisite binding ensures strict selectivity toward light-activated phosphorylated rhodopsin. J Biol Chem. 1993; 268:11628-11638.
74. Gurevich VV, Gurevich EV. The molecular acrobatics of arrestin activation. Trends Pharmacol Sci. 2004;25:105-111.
75. Palczewski K, Buczylko J, Kaplan MW, Polans AS, Crabb JW. Mechanism of rhodopsin kinase activation. J Biol Chem. 1991; 266:12949-12955.
76. Gurevich VV, Gurevich EV. The structural basis of arrestin-medi-ated regulation of G-protein-coupled receptors. Pharmacol Ther. 2006;110:465-502.
77. DeFea KA. /3-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold? Cell Signal. 2011;23:621-629.
78. Lefkowitz RJ, Whalen EJ. /3-Arrestins: traffic cops of cell signaling. Curr Opin Cell Biol. 2004;16:162-168.
79. Perry SJ, Baillie GS, Kohout TA, et al. Targeting of cyclic AMP degradation to /32-adrenergic receptors by /3-arrestins. Science. 2002;298:834-836.
80. Imamura T, Huang J, Dalle S, et al. /3-Arrestin-mediated recruitment of the Src family kinase Yes mediates endothelin-1-stimulated glucose transport. J Biol Chem. 2001;276:43663-43667.
81. DeFea KA, Vaughn ZD, O’Bryan EM, Nishijima D, Dery O, Bun-nett NW. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a /3-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA. 2000;97:11086-11091.
82. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. /3-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 2000;148:1267-1281.
83. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA. 2001;98:2449-2454.
84. McDonald PH, Chow CW, Miller WE, et al. /3-Arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 2000;290:1574-1577.
85. Coffa S, Breitman M, Hanson SM, et al. The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation. PLoS One. 2011;6:e28723.
86. Tohgo A, Choy EW, Gesty-Palmer D, et al. The stability of the G protein-coupled receptor-/3-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem. 2003;278:6258-6267.
87. Wei H, Ahn S, Barnes WG, Lefkowitz RJ. Stable interaction between /3-arrestin 2 and angiotensin type 1A receptor is required for /3-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2. J Biol Chem. 2004;279:48255-48261.
88. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct /3-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 2006;281: 10856-10864.
89. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G. /3-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA. 2003;100:11406-11411.
90. Datta NS, Kolailat R, Fite A, Pettway G, Abou-Samra AB. Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cell Signal. 2010;22:457-466.
91. Teyra J, Sidhu SS, Kim PM. Elucidation of the binding preferences of peptide recognition modules: SH3 and PDZ domains. FEBS Lett. 2012;586:2631-2637.
92. Romero G, von Zastrow M, Friedman PA. Role of PDZ proteins in regulating trafficking, signaling, and function of GPCRs: means, motif, and opportunity. Adv Pharmacol. 2011;62:279-314.
93. Cao TT, Deacon HW, Reczek D, Bretscher A, von Zastrow M. A kinase-regulated PDZ-domain interaction controls endocytic sorting of the /32-adrenergic receptor. Nature. 1999;401:286-290.
94. Hall RA, Premont RT, Chow CW, et al. The /32-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature. 1998;392:626-630.
95. Hu LA, Tang Y, Miller WE, et al. /31-Adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of /31-adrenergic receptor interaction with N-methyl-D-aspartate receptors. J Biol Chem. 2000;275:38659-38666.
96. Gardner LA, Naren AP, Bahouth SW. Assembly of an SAP97-AKAP79-cAMP-dependent protein kinase scaffold at the type 1 PSD-95/DLG/ZO1 motif of the human /3(1)-adrenergic receptor generates a receptosome involved in receptor recycling and networking. J Biol Chem. 2007;282:5085-5099.
97. He J, Bellini M, Inuzuka H, et al. Proteomic analysis of /31-adrenergic receptor interactions with PDZ scaffold proteins. J Biol Chem. 2006;281:2820-2827.
98. Nakagawa T, Asahi M. /31-Adrenergic receptor recycles via a membranous organelle, recycling endosome, by binding with sorting nexin27. J Membr Biol. 2013;246:571-579.
99. Nooh MM, Chumpia MM, Hamilton TB, Bahouth SW. Sorting of /31-adrenergic receptors is mediated by pathways that are either dependent on or independent of type I PDZ, protein kinase A (PKA), and SAP97. J Biol Chem. 2014;289:2277-2294.
100. Xu J, Paquet M, Lau AG, Wood JD, Ross CA, Hall RA. /31-Adrenergic receptor association with the synaptic scaffolding protein membrane-associatedguanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization by MAGI-2 and PSD-95. J Biol Chem. 2001;276:41310-41317.
101. He J, Bellini M, Xu J, Castleberry AM, Hall RA. Interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits /31-adrenergic receptor surface expression. J Biol Chem. 2004;279:50190-50196.
102. Bauch C, Koliwer J, Buck F, Honck HH, Kreienkamp HJ. Subcellular sorting of the G-protein coupled mouse somatostatin receptor 5 by a network of PDZ-domain containing proteins. PLoS One. 2014;9:e88529.
103. Wente W, Stroh T, Beaudet A, Richter D, Kreienkamp HJ. Interactions with PDZ domain proteins PIST/GOPC and PDZK1 regulate intracellular sorting of the somatostatin receptor subtype 5. J Biol Chem. 2005;280:32419-32425.
104. Koliwer J, Park M, Bauch C, von Zastrow M, Kreienkamp HJ. The golgi-associated PDZ domain protein PIST/GOPC stabilizes the /31-adrenergic receptor in intracellular compartments after internalization. J Biol Chem. 2015;290:6120-6129.
105. Stroh T, Jackson AC, Sarret P, et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology. 2000;141:354-365.
106. Lauffer BE, Melero C, Temkin P, et al. SNX27 mediates PDZ-directed sorting from endosomes to the plasma membrane. J Cell Biol. 2010;190:565-574.
107. Temkin P, Lauffer B, Jager S, Cimermancic P, Krogan NJ, von Zastrow M. SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors. Nat Cell Biol. 2011;13:715-721.
108. Liew CW, Vockel M, Glassmeier G, et al. Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett. 2009;583:49-54.
109. Guillaume JL, Daulat AM, Maurice P, et al. The PDZ protein mupp1 promotes Gi coupling and signaling of the Mt1 melatonin receptor. J Biol Chem. 2008;283:16762-16771.
110. Becamel C, Figge A, Poliak S, et al. Interaction of serotonin 5-hy-droxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. J Biol Chem. 2001;276:12974-12982.
111. Parker LL, Backstrom JR, Sanders-Bush E, Shieh BH. Agonist-induced phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple PDZ protein 1. J Biol Chem. 2003;278:21576-21583.
112. Ullmer C, Schmuck K, Figge A, Lubbert H. Cloning and characterization of MUPP1, a novel PDZ domain protein. FEBS Lett. 1998;424:63-68.
113. Hanyaloglu AC, von Zastrow M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol. 2008;48:537-568.
114. Jean-Alphonse F, Bowersox S, Chen S, Beard G, Puthenveedu MA, Hanyaloglu AC. Spatially restricted G protein-coupled receptor activity via divergent endocytic compartments. J Biol Chem. 2014;289:3960-3977.
115. Jeanneteau F, Diaz J, Sokoloff P, Griffon N. Interactions of GIPC with dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-coupled receptors. Mol Biol Cell. 2004; 15:696-705.
116. Jeanneteau F, Guillin O, Diaz J, Griffon N, Sokoloff P. GIPC recruits GAIP (RGS19) to attenuate dopamine D2 receptor signaling. Mol Biol Cell. 2004;15:4926-4937.
117. Klenk C, Vetter T, Zurn A, et al. Formation of a ternary complex among NHERF1, /3-arrestin, and parathyroid hormone receptor. J Biol Chem. 2010;285:30355-30362.
118. Kim JK, Kwon O, Kim J, et al. PDZ domain-containing 1 (PDZK1) protein regulates phospholipase C-/33 (PLC-/33)-specific activation of somatostatin by forming a ternary complex with PLC-/33 and somatostatin receptors. J Biol Chem. 2012;287: 21012-21024.
119. Choi JW, Lim S, OH YS, et al. Subtype-specific role of phospholipase C-/3 in bradykinin and LPA signaling through differential binding of different PDZ scaffold proteins. Cell Signal. 2010;22: 1153-1161.
120. Oh YS, Jo NW, Choi JW, et al. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-/33 activation. Mol Cell Biol. 2004; 24:5069-5079.
121. Mahon MJ, Donowitz M, Yun CC, Segre GV. Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature. 2002;417:858-861.
122. Wang B, Yang Y, Abou-Samra AB, Friedman PA. NHERF1 regulates parathyroid hormone receptor desensitization: interference with /3-arrestin binding. Mol Pharmacol. 2009;75:1189-1197.
123. Rochdi MD, Watier V, LA Madeleine C, Nakata H, Kozasa T, Parent JL. Regulation of GTP-binding protein alpha q (Gaq) signaling by the ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50). J Biol Chem. 2002;277:40751-40759.
124. Fam SR, Paquet M, Castleberry AM, et al. P2Y1 receptor signaling is controlled by interaction with the PDZ scaffold NHERF-2. Proc Natl Acad Sci USA. 2005;102:8042-8047.
125. Hall RA, Ostedgaard LS, Premont RT, et al. A C-terminal motif found in the /32-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci USA. 1998;95:8496-8501.
126. Dunn HA, Walther C, Godin CM, Hall RA, Ferguson SS. Role of SAP97 protein in the regulation of corticotropin-releasing factor receptor 1 endocytosis and extracellular signal-regulated kinase 1/2 signaling. J Biol Chem. 2013;288:15023-15034.
127. Walther C, Caetano FA, Dunn HA, Ferguson SS. PDZK1/NH-ERF3 differentially regulates corticotropin-releasing factor recep- tor 1 and serotonin 2A receptor signaling and endocytosis. Cell Signal. 2015;27:519-531.
128. Xia Z, Gray JA, Compton-Toth BA, Roth BL. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem. 2003;278: 21901-21908.
129. Reid HM, Turner EC, Mulvaney EP, Hyland PB, McLean C, Kinsella BT. Interaction of the human prostacyclin receptor and the NHERF4 family member intestinal and kidney enriched PDZ protein (IKEPP). Biochim Biophys Acta. 2012;1823:1998-2012.
130. Sarrouilhe D, diTommaso A, Metaye T, Ladeveze V. Spinophilin: from partners to functions. Biochimie. 2006;88:1099-1113.
131. Brady AE, Wang Q, Allen PB, Rizzo M, Greengard P, Limbird LE. a2-Adrenergic agonist enrichment of spinophilin at the cell surface involves 187 subunits of Gi proteins and is preferentially induced by the a2A-subtype. Mol Pharmacol. 2005;67:1690-1696.
132. Richman JG, Brady AE, Wang Q, Hensel JL, Colbran RJ, Limbird LE. Agonist-regulated Interaction between o2-adrenergic receptors and spinophilin. J Biol Chem. 2001;276:15003-15008.
133. Smith FD, Oxford GS, Milgram SL. Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J Biol Chem. 1999;274: 19894-19900.
134. Brady AE, Wang Q, Colbran RJ, Allen PB, Greengard P, Limbird LE. Spinophilin stabilizes cell surface expression of o2B-adrener-gic receptors. J Biol Chem. 2003;278:32405-32412.
135. Wang Q, Limbird LE. Regulated interactions of the a2A adrenergic receptor with spinophilin, 14–3–3f, and arrestin 3. J Biol Chem. 2002;277:50589-50596.
136. Wang Q, Zhao J, Brady AE, et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science. 2004;304:1940-1944.
137. Wang X, Zeng W, Soyombo AA, et al. Spinophilin regulates Ca2 + signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell Biol. 2005;7:405-411.
138. Lu R, Chen Y, Cottingham C, et al. Enhanced hypotensive, bradycardic, and hypnotic responses to o2-adrenergic agonists in spi-nophilin-null mice are accompanied by increased G protein coupling to the o2A-adrenergic receptor. Mol Pharmacol. 2010;78: 279-286.
139. Ruiz de Azua I, Nakajima K, Rossi M, et al. Spinophilin as a novel regulator of M3 muscarinic receptor-mediated insulin release in vitro and in vivo. FASEB J. 2012;26:4275-4286.
140. Charlton JJ, Allen PB, Psifogeorgou K, et al. Multiple actions of spinophilin regulate mu opioid receptor function. Neuron. 2008; 58:238-247.
141. Colledge M, Scott JD. AKAPs: from structure to function. Trends Cell Biol. 1999;9:216-221.
142. Cong M, Perry SJ, Lin FT, et al. Regulation of membrane targeting of the G protein-coupled receptor kinase 2 by protein kinase A and its anchoring protein AKAP79. J Biol Chem. 2001;276:15192-15199.
143. Fan G, Shumay E, Wang H, Malbon CC. The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the /32-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization. J Biol Chem. 2001;276:24005-24014.
144. Fraser ID, Cong M, Kim J, et al. Assembly of an A kinase-anchoring protein-/3 (2)-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr Biol. 2000;10:409-412.
145. Shih M, Lin F, Scott JD, Wang HY, Malbon CC. Dynamic complexes of /32-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J Biol Chem. 1999;274:1588-1595.
146. Li X, Nooh MM, Bahouth SW. Role of AKAP79/150 protein in /31-adrenergic receptor trafficking and signaling in mammalian cells. J Biol Chem. 2013;288:33797-33812.
147. Nooh MM, Naren AP, Kim SJ, Xiang YK, Bahouth SW. SAP97 controls the trafficking and resensitization of the /31-adrenergic receptor through its PDZ2 and I3 domains. PLoS One. 2013;8: e63379.
148. Broselid S, Berg KA, Chavera TA, et al. G protein-coupled receptor 30 (GPR30) forms a plasma membrane complex with membrane-associated guanylate kinases (MAGUKs) and protein kinase A-anchoring protein 5 (AKAP5) that constitutively inhibits cAMP production. J Biol Chem. 2014;289:22117-22127.
149. Ali MS, Sayeski PP, Bernstein KE. Jak2 acts as both a STAT1 kinase and as a molecular bridge linking STAT1 to the angiotensin II AT1 receptor. J Biol Chem. 2000;275:15586-15593.
150. Kodama H, Fukuda K, Pan J, et al. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ Res. 1998;82:244-250.
151. Marrero MB, Schieffer B, Paxton WG, et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature. 1995;375:247-250.
152. McWhinney CD, Dostal D, Baker K. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes. J Mol Cell Cardiol. 1998;30:751-761.
153. McWhinney CD, Hunt RA, Conrad KM, Dostal DE, Baker KM. The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 1997;29:2513-2524.
154. Pan J, Fukuda K, Kodama H, et al. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. Circ Res. 1997;81:611-617.
155. Sayeski PP, Ali MS, Frank SJ, Bernstein KE. The angiotensin II-dependent nuclear translocation of Stat1 is mediated by the Jak2 protein motif 231YRFRR. JBiolChem. 2001;276:10556-10563.
156. Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB, Bernstein KE. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem. 1997;272:23382-23388.
157. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol. 1998;275:C1216-C1223.
158. Van Der Hoeven PC, Van Der Wal JC, Ruurs P, Van Dijk MC, Van Blitterswijk J. 14-3-3 isotypes facilitate coupling of protein kinase Cf to Raf-1: negative regulation by 14-3-3 phosphorylation. Biochem J. 2000;345(Pt 2):297-306.
159. Cohen BD, Nechamen CA, Dias JA. Human follitropin receptor (FSHR) interacts with the adapter protein 14-3-3tau. Mol Cell Endocrinol. 2004;220:1-7.
160. Shikano S, Coblitz B, Wu M, Li M. 14-3-3 proteins: regulation of endoplasmic reticulum localization and surface expression of membrane proteins. Trends Cell Biol. 2006;16:370-375.
161. Yuan H, Michelsen K, Schwappach B. 14-3-3 dimers probe the assembly status of multimeric membrane proteins. Curr Biol. 2003;13:638-646.
162. Cunningham MR, McIntosh KA, Pediani JD, et al. Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4). J Biol Chem. 2012; 287:16656-16669.
163. Okamoto Y, Shikano S. Phosphorylation-dependent C-terminal binding of 14-3-3 proteins promotes cell surface expression of HIV co-receptor GPR15. J Biol Chem. 2011;286:7171-7181.
164. Prezeau L, Richman JG, Edwards SW, Limbird LE. The f isoform of 14-3-3 proteins interacts with the third intracellular loop of different o2-adrenergic receptor subtypes. J Biol Chem. 1999;274: 13462-13469.
165. Wang Q, Limbird LE. Regulation of a2AR trafficking and signal- ing by interacting proteins. Biochem Pharmacol. 2007;73:1135-1145.
166. Lania AG, Mantovani G, Spada A. Mechanisms of disease: mutations of G proteins and G-protein-coupled receptors in endocrine diseases. Nat Clin Pract Endocrinol Metab. 2006;2:681-693.
167. Kimple ME, Neuman JC, Linnemann AK, Casey PJ. Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes. Exp Mol Med. 2014;46:e102.
168. Sivertsen B, Holliday N, Madsen AN, Holst B. Functionally biased signalling properties of 7TM receptors—opportunities for drug development for the ghrelin receptor. Br J Pharmacol. 2013; 170:1349-1362.
169. Evron T, Peterson SM, Urs NM, et al. G Protein and /3-arrestin signaling bias at the ghrelin receptor. J Biol Chem. 2014;289: 33442-33455.
170. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-846.
171. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8:369-385.
172. Kong KC, Tobin AB. The role of M(3)-muscarinic receptor signaling in insulin secretion. Commun Integr Biol. 2011;4:489-491.
173. Guettier JM, Gautam D, Scarselli M, et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci USA. 2009;106:19197-19202.
174. Jain S, Ruiz de Azua I, Lu H, White MF, Guettier JM, Wess J. Chronic activation of a designer G(q)-coupled receptor improves /3 cell function. J Clin Invest. 2013;123:1750-1762.
175. Nakajima K, Wess J. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol. 2012;82:575-582.
176. Kong KC, Butcher AJ, McWilliams P, et al. M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arres-tin-dependent activation of protein kinase D1. Proc Natl Acad Sci USA. 2010;107:21181-21186.
177. Nakajima K, Jain S, Ruiz de Azua I, McMillin SM, Rossi M, Wess J. Minireview: novel aspects of M3 muscarinic receptor signaling in pancreatic /3-cells. Mol Endocrinol. 2013;27:1208-1216.
178. Ruiz de Azua I, Scarselli M, Rosemond E, et al. RGS4 is a negative regulator of insulin release from pancreatic /3-cells in vitro and in vivo. Proc Natl Acad Sci USA. 2010;107:7999-8004.
179. Wente W, Efanov AM, Treinies I, et al. The PDZ/coiled-coil domain containing protein PIST modulates insulin secretion in MIN6 insulinoma cells by interacting with somatostatin receptor subtype 5. FEBS Lett. 2005;579:6305-6310.
180. Curtis JR, Safford MM. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging. 2012; 29:549-564.
181. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004;15:60-65.
182. Taylor CW, Tovey SC. From parathyroid hormone to cytosolic Ca2+ signals. Biochem Soc Trans. 2012;40:147-152.
183. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Cat-abolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest. 2011;34:801-810.
184. Gesty-Palmer D, Luttrell LM.’Biasing’ the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? BrJ Pharmacol. 2011;164:59-67.
185. Gesty-Palmer D, Flannery P, Yuan L, et al. A /3-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med. 2009;1:1ra1.
186. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79-94.
187. Rodien P, Ho SC, Vlaeminck V, Vassart G, Costagliola S. Activating mutations of TSH receptor. Ann Endocrinol (Paris). 2003; 64:12-16.
188. O’Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014;27:126-135.
189. Chun KS, Lao HC, Trempus CS, Okada M, Langenbach R. The prostaglandin receptor EP2 activates multiple signaling pathways and /3-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis. 2009;30:1620-1627.
190. Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4-/3Arrestin1-c-Src sig-nalsome. Mol Cancer Res. 2010;8:569-577.
191. Li TT, Alemayehu M, Aziziyeh AI, et al. /3-Arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res. 2009;7:1064-1077.
192. Rosano L, Bagnato A. Convergent pathways link the endothelin A receptor to the /3-catenin: the beta-arrestin connection. Cell Cycle. 2009;8:1462-1463.
193. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of /3-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA. 2006;103:1492-1497.
194. Zhang P, He X, Tan J, Zhou X, Zou L. /3-Arrestin2 mediates /3-2 adrenergic receptor signaling inducing prostate cancer cell progression. Oncol Rep. 2011;26:1471-1477.
195. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of /3-arrestin- and G protein-biased agonists. Trends Mol Med. 2011; 17:126-139.
196. Lakshmikanthan V, Zou L, Kim JI, et al. Identification of /3Arrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA. 2009;106:9379-9384.
197. Purayil HT, Zhang Y, Dey A, Gersey Z, Espana-Serrano L, Daaka Y. Arrestin2 modulates androgen receptor activation [published online August 11, 2014]. Oncogene. doi:10.1038/onc.2014.252.
198. Ress AL, Stiegelbauer V, Schwarzenbacher D, et al. Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. Oncotarget. 2014; 5:8492-8502.
199. Subbaiah VK, Kranjec C, Thomas M, Banks L. PDZ domains: the building blocks regulating tumorigenesis. Biochem J. 2011;439: 195-205.
200. Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, Pan Y. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer. Oncogene. 2004;23:8681-8687.
201. Hayashi Y, Molina JR, Hamilton SR, Georgescu MM. NHERF1/ EBP50 is a new marker in colorectal cancer. Neoplasia. 2010;12: 1013-1022.
202. Muders MH, Dutta SK, Wang L, et al. Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Res. 2006;66:10264-10268.
203. Muders MH, Vohra PK, Dutta SK, et al. Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res. 2009;15:4095-4103.
204. Aubry JM. CRF system and mood disorders. J Chem Neuroanat. 2013;54:20-24.
205. Leonard BE. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry. 2005;20(suppl 3): S302-S306.
206. Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta. 2007;1768:976-993.
207. Magalhaes AC, Holmes KD, Dale LB, et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci. 2010;13:622-629.
208. Dunn HA, Walther C, Yuan GY, Caetano FA, Godin CM, Fergu- son SS. Role of SAP97 in the regulation of 5-HT2AR endocytosis and signaling. Mol Pharmacol. 2014;86:275-283.
209. Fribourg M, Moreno JL, Holloway T, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell. 2011;147:1011-1023.
210. Zhang J, Cheng S, Xiong Y, et al. A novel association of mGluR1a with the PDZ scaffold protein CAL modulates receptor activity. FEBS Lett. 2008;582:4117-4124.
211. Paquet M, Asay MJ, Fam SR, et al. The PDZ scaffold NHERF-2 interacts with mGluR5 and regulates receptor activity. J Biol Chem. 2006;281:29949-29961.
212. Hu LA, Chen W, Martin NP, Whalen EJ, Premont RT, Lefkowitz RJ. GIPC interacts with the /31-adrenergic receptor and regulates /31-adrenergic receptor-mediated ERK activation. J Biol Chem. 2003;278:26295-26301.
213. Yang X, Zheng J, Xiong Y, et al. /32 Adrenergic receptor mediated ERK activation is regulated by interaction with MAGI-3. FEBS Lett. 2010;584:2207-2212.
214. Zhang H, Wang D, Sun H, Hall RA, Yun CC. MAGI-3 regulates LPA-induced activation of Erk and RhoA. Cell Signal. 2007;19: 261-268.
215. Wang B, Ardura JA, Romero G, Yang Y, Hall RA, Friedman PA. Na/H exchanger regulatory factors control parathyroid hormone receptor signaling by facilitating differential activation of G« protein subunits. J Biol Chem. 2010;285:26976-26986.
216. Wheeler D, Garrido JL, Bisello A, Kim YK, Friedman PA, Romero G. Regulation of parathyroid hormone type 1 receptor dynamics, traffic, and signaling by the Na+/H+ exchanger regulatory fac-tor-1 in rat osteosarcoma ROS 17/2.8 cells. Mol Endocrinol. 2008;22:1163-1170.
217. Zhang J, Vinuela A, Neely MH, et al. Inhibition of the dopamine D1 receptor signaling by PSD-95.J BiolChem. 2007;282:15778-15789.
218. Katsushima Y, Sato T, Yamada C, et al. Interaction of PICK1 with C-terminus of growth hormone-releasing hormone receptor (GHRHR) modulates trafficking and signal transduction of human GHRHR. J Pharmacol Sci. 2013;122:193-204.